Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) — Working Capital to Net Assets Ratio
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has a Working Capital to Net Assets ratio of 104.8% as of March 2026. Working capital of $-2.98 Million (current assets of $50.63K minus current liabilities of $3.03 Million) is measured against net assets of $-2.84 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Lakewood-Amedex Biotherapeutics Inc. Common Stock Working Capital to Net Assets (2023–2025)
This chart shows how Lakewood-Amedex Biotherapeutics Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 3 annual periods from 2023 to 2025. As of March 2026, the ratio stands at 104.8%, reflecting working capital of $-2.98 Million against net assets of $-2.84 Million USD. See Lakewood-Amedex Biotherapeutics Inc. Com (LABT) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2023 to 2025, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see LABT total asset value.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 106.9% | $-2.10 Million | $-1.96 Million | $305.39K | $2.41 Million | ▲ +40.1 pp |
| 2024 | 66.7% | $273.35K | $409.61K | $773.98K | $500.63K | ▼ -30.2 pp |
| 2023 | 96.9% | $4.42 Million | $4.56 Million | $6.48 Million | $2.06 Million | — |